Vigencell

Developer of T-cell therapy for tumour development

placeSeoul, Seoul, South Korea calendar_todayFounded 2013 groups80 employees language vigencell.com

Investor mix

4 investors on record.

Investor typeCountShare
Venture capital125%
Private equity375%
Coming soon